Frontiers in Oncology
Case Report: Safety and efficacy of tarlatamab for SCLC in a liver transplant recipient
By Jonas Leonhardt, Johann Pratschke, Jürgen Behr and 7 others.
Abstract
Tarlatamab is a bispecific T-cell engager used for the treatment of small cell lung cancer (SCLC). Patients with a history of solid organ transplantation carry an elevated risk of malignancy yet are excluded from most clinical trials. We report the first case of Tarlatamab use in a liver transplant recipient with SCLC, resulting in marked tumor response and a favorable safety profile without evidence of graft rejection.
Keywords
- delta-like ligand 3
- small cell lung cancer
- solid organ transplant recipient
- targeted therapy
- tarlatamab
Source
Published in Frontiers in Oncology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
More in oncology
- The value of breast brachytherapy boost in the current era: a narrative literature review from the GEC-ESTRO breast cancer working groupClinical and Translational Radiation Oncology · 2026
- Academic treatment optimization studies in oncology and internal medicine: a risk- and burden-adapted regulatory framework for the European UnionThe Lancet Regional Health. Europe · 2026
